BNMS 2024
In the PSMA era, is there still a place for Xofigo▼ (radium-223 dichloride) in the management of advanced prostate cancer?

An on demand video of the Bayer-sponsored symposium at the British Nuclear Medicine Society (BNMS) Spring Meeting 2024, which took place in Belfast on the 15th May 2024. In this session Professor Joe O'Sullivan, Clinical Oncologist, Northern Ireland Cancer Centre articulates the potential impact of radionuclide therapies on managing prostate cancer, with a specific focus on radium-223.
This symposium was organised and funded by Bayer.
Abbreviations: PSMA; prostate-specific membrane antigen
PP-XOF-GB-0598 | January 2025